TriLink BioTechnologies (TriLink), announced that it has signed a sales and license agreement with Glen Research Corporation to sell TriLink's CleanAmp™ Amidites.
Glen Research can now sell the patented CleanAmp™ Amidites produced by TriLink to third parties for use in the production of CleanAmp™ Primers.
TriLink's CleanAmp™ technology offers a less expensive approach to high stringency PCR. CleanAmp™ is a unique solution, where the primer or dNTP components of the PCR reaction mix, rather than the enzymes are modified.
Making the CleanAmp™ Amidites available through Glen Research allows institutions with oligonucleotide synthesis capabilities to manufacture CleanAmp™ Primers in-house.
"Glen Research is dedicated to bringing the very best research products to the oligonucleotide synthesis market. So we are delighted to be able to offer CleanAmp™ Amidites in partnership with TriLink. We feel that the CleanAmp™ Amidites will make an excellent addition to our repertoire of products for DNA research," said Glen Research President/CEO, Dr. Hugh Mackie.
"TriLink and Glen Research have a long standing relationship built on a shared interest in advancing science through the highest quality reagents and technical expertise. We feel Glen Research is the perfect partner for bringing CleanAmp™ Amidites to the marketplace," said TriLink CEO, Dr. Richard Hogrefe.